Retraction to: Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells (Int. J. Cancer, (2006), 119, (2071–2077), 10.1002/ijc.22077);Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells

International Journal of Cancer

Volumn 119, Issue 9, 2006, Pages 2071-2077

  Zhang, Yuxiang ^a   Wang, Zliiwei ^b   Ahmed, Fakhara ^b   Banerjee, Sanjeev ^b   Li, Yiwei ^b   Sarkar, Fazlul H ^b,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c 740 HWCRC ^*  (United States)

Author keywords

Cell growth; Jagged 1; Prostate cancer; S phase

Indexed keywords

CYCLIN DEPENDENT KINASE 2; JAGGED1; NOTCH RECEPTOR; PROTEIN P27;

ARTICLE; BENIGN TUMOR; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL FATE; CELL SPECIFICITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STEM CELL;

EID: 33748872289     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30268     Document Type: Erratum

References (26)

1. Landis SH, Murray T, Bolden PA. Cancer statistics 1999. Cancer 1999;49:8-31.
2. Yong EL, Lim J, Qi W, Ong V, Mifsud A. Molecular basis of androgen receptor diseases. Ann Med 2000;32:15-22.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
4. Artavanis-Tsakonas S, Rand MD Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6.
5. Gray GE, Mann RS, Mitsiadis E, Henrique D, Carcangiu ML, Banks A, Leiman J, Ward D, Ish-Horowitz D, Artavanis-Tsakonas S. Human ligands of the Notch receptor. Am J Surg Pathol 1999;154:785-94.
6. Miele L, Osborne BA. Arbiter of differentiation and death: notch signaling meets apoptosis. J Cell Physiol 1999;181:393-409.
7. Weng AP, Aster JC. Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev 2004;14:48-54.
8. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, Achilleos M, Greenberger LM, Frost P, Bai W, Zhang Y. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 2004;145:3913-24.
9. Dalrymple S, Antony L, Xu Y, Uzgare AR, Arnold JT, Savaugeot J, Sokoll LJ, De Marzo AM, Isaacs JT. Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res 2005;65:9269-79.
10. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, Aebersold R, Nelson PS. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004;64:347-55.
11. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin MA, Aster JC. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004;64:6854-7.
12. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, Hui CC, Clevers H, Dotto GP, Radtke F. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003;33:416-21.
13. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, Ball DW. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001;61:3200-5.
14. Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, Maric D, Eberhart CG et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged1, is critical for glioma cell survival and proliferation. Cancer Res 2005;65:2353-63.
15. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
16. Weng AP, Nam Y, Wolfe MS, Pear WS, Griffin JD, Blacklow SC, Aster JC. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of Notch signaling. Mol Cell Biol 2003;23:655-64.
17. Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res 2001;61:7291-7.
18. LaVoie MJ, Selkoe DJ. The Notch ligands. Jagged and Delta, are sequentially processed by α-secretase and presenilin/γ-secretase and release signaling fragments. J Biol Chem 2003;278:34427-37.
19. Ascano JM, Beverly LJ, Capobianco AJ. The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J Biol Chem 2003;278:8771-9.
20. Machida YJ, Hamlin JL. Right place, right time, and only once: replication initiation in metazoans. Cell 2005;123:13-24.
21. Fischer PM. The use of CDK inhibitors in oncology: a pharmaceutical perspective. Cell Cycle 2004;3:742-6.
22. Gladden AB, Diehl JA. Cell cycle progression without cyclin E/CDK2: breaking down the walls of dogma. Cancer Cell 2003;4:160-2.
23. Macri E, Loda M, Ettore M, Massimo L. Role of p27 in Prostate Carcinogenesis. Cancer Metastasis Rev 1999;17:337-44.
24. Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol 2001;21:5925-34.
25. Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997;3:2269-74.
26. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003;9:1474-9.